The Novavax vaccine is 90.4 per cent effective at preventing COVID-19 infection, according to the company’s phase 3 trial.
Novavax gave at least one dose of the vaccine to nearly 20,000 people, with about 10,000 receiving a placebo (sugar pill). Over three months, 14 vaccinated participants tested positive to COVID-19 and 77 placebo participants tested positive.
Ten moderate and four severe cases occurred, all in the placebo group. Of the COVID-19 cases that were sequenced, four in five were a variant of interest or variant of concern.
Soon updating more…
Source: 10.1056/NEJMoa2116185
You were reading: Novavax reports 90.4% efficacy against COVID-19 infection
